RETN and obesity disorder: Consistent with the reduction of obesity, treatment of KY19334, but not orlistat, specifically improved their metabolic parameters including total cholesterol, HDL-cholesterol, leptin, and resistin as well as the blood glucose level and insulin sensitivity (Fig. 2E–G and Supplemental Fig. 3E–G).